Clinical Trial Search

Primary: Percentage of Participants With Positive Anti-etanercept Binding Antibody Response During the Study — 3.8 percentage of participants

Primary: Upper Extremity Fugl-Meyer Score — 23.8; 31.5; 31.9; 37 units on a scale — p=0.05

Primary: Implant Stability Quotient (ISQ) Value as a Measure of Implant Stability in Bone — 79.6; 80.1; 79.7; 79.7 units on a scale — p=<0.01

Primary: Number of Seroprotected Subjects Against Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T). — 7; 28; 10; 34 Participants

Primary: Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936. — 0.29; 0.50; 0.29…

Primary: Time to Hemostasis — 1.78 minutes

Primary: Readiness to Attend Substance Use Disorder Continuing Care — 1.8; 2.2 units on a scale — p=<.05

Primary: P2Y12 Reaction Units (PRU) — 95; 164 PRU — p=0.022

Primary: Number of Participants With Peanut Allergy at 60 Months of Age - by Skin Prick Test Stratum — 36; 5; 18; 5 Participants — p=<0.0001

Primary: Liebowitz Social Anxiety Scale — 56.80; 60.94; 52.05; 55.05 units on a scale — p==.40

Primary: Number of Participants Who Forwarded the Video — 221; 215; 44; 37 participants — p=0.44

Primary: Plasma Concentration of Total Dabigatran (SUM BIBR 953 ZW) — 79.4; 90.6; NA; 129.0 ng/mL

Primary: Phase I: Number of Participants Experiencing at Least One Dose-Limiting Toxicity (DLT) Adverse Event (AE) During the First Four Weeks of Dalotuzumab Plus Erlotinib…

Primary: Change in HbA1c Values From Baseline Measurement — 2.4; 2.2; 0.8; 1.6 percentage of HbA1c

Primary: Preference for Shared Decision Making — 22; 19; 35; 44 participants